Neurogene (NASDAQ:NGNE) Announces Earnings Results

Neurogene (NASDAQ:NGNE) posted its quarterly earnings results on Monday. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.05, Zacks reports.

Neurogene Price Performance

NASDAQ NGNE opened at $13.96 on Tuesday. The company’s 50-day simple moving average is $17.09 and its 200 day simple moving average is $29.30. Neurogene has a twelve month low of $13.47 and a twelve month high of $74.49.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Neurogene in a research report on Monday, November 25th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $60.80.

Insiders Place Their Bets

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total transaction of $76,246.94. Following the completion of the sale, the chief financial officer now owns 72,343 shares of the company’s stock, valued at approximately $1,225,490.42. This trade represents a 5.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 9.92% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.